E. coli evolutionary map could lead to precision medicine against antibiotic resistance
The first-of-its-kind in-depth bacterial evolutionary map could pave the way for the development of precision treatments for ...
The Hoya8d
THE REPRO RUNDOWN | Understanding Urinary Tract Infections: Why Do We Get UTIs?
As I perused the latest edition of Georgetown’s leading publication — the Stall Seat Journal — I was pleased to see a brief ...
Al Día News10d
After 30 Years, a New Antibiotic for Urinary Tract Infections Arrives
The FDA has approved the drug for use in women and girls over the age of 12 who suffer from uncomplicated urinary tract ...
News Medical on MSN2d
New bacterial evolutionary map could lead to precision treatments for infections
The first-of-its-kind in-depth bacterial evolutionary map could pave the way for the development of precision treatments for certain antibiotic-resistant infections, such as urinary tract infections.
Hosted on MSN11d
FDA Approves Blujepa for Uncomplicated Urinary Tract Infections
TUESDAY, March 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Blujepa (gepotidacin) for the ...
PMLive9d
GSK’s antibiotic Blujepa granted FDA approval to treat urinary tract infections
GSK’s oral antibiotic Blujepa (gepotidacin) has been approved by the US Food and Drug Administration (FDA) to treat ...
Zacks.com on MSN10d
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection
The FDA approval is based on late-stage data, which shows that GSK's Blujepa is at least as effective as a leading standard treatment for uncomplicated UTIs.
Everyday Health9d
FDA Approves the First New UTI Antibiotic in Nearly 30 Years
Blujepa (gepotidacin) is the first new antibiotic class approved in nearly 30 years, providing a crucial treatment option for drug-resistant urinary tract infections (UTIs). In clinical trials ...
Pharmabiz9d
GSK’s Blujepa receives US FDA nod to treat uncomplicated urinary tract infections in female and paediatric patients 12 years of age and older
GSK’s Blujepa receives US FDA nod to treat uncomplicated urinary tract infections in female and paediatric patients 12 years of age and older: Philadelphia Friday, March 28, 202 ...